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Abstract 
Background: Cytokines have been implicated in the pathophysiology of depression in adults, 
however the potential role in younger age groups such as adolescents is less clear. We review 
the literature (i) exploring the relationship between cytokines and depression in adolescents 
and (ii) examining how cytokines may be related to adolescent depression in the context of 
other neurobiological theories of depression. 
Method: A systematic review of the scientific literature on the subject was conducted in 
February 2013, searching the Web of Knowledge, PubMed (Medline), PsycInfo, and Cochrane 
electronic databases. 
Results: Eighteen studies were identified measuring both depression or depressive symptoms 
and cytokines or immune markers in adolescents. Adolescents with depression show age 
specific characteristics of the immune and inflammatory system, specifically in NK cell activity 
and in pro-inflammatory cytokines (such as IL-1β and TNF-α). In addition, the role of cytokines 
in adolescent depression is influenced by neurodevelopment, hormonal changes, stress, and 
trauma.  
Conclusions: There may be differences in the neurobiology of adolescent MDD compared to 
adult MDD. Increased understanding of the role of cytokines in adolescent MDD may lead to 
improved outcomes in the treatment of adolescent depression. 
 
Key Words:  Cytokines, inflammation, immune system, adolescents, depression, cognition, 
stress 
 
 3 
Abbreviations: MDD=Major Depressive Disorder; CD=Conduct Disorder; HPA=Hypothalamic-
Pituitary-Adrenal; IL=interleukin; TNF-α=tumor necrosis factor-α; IFN-γ=interferon-γ; NK cells 
=natural killer cells; TRP=tryptophan; KYN=kynurenine; 3-HAA=3-hydroxyanthranilic acid; 
QUIN=quinolinic acid; tCho=total choline; PUFAs=polyunsaturated fatty acids; CRH= 
corticotrophin-releasing hormone; CRP=C-reactive protein; LPS=lipopolysaccharide; 
SSRI=selective serotonin re-uptake inhibitor 
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Introduction 
Major depression is a leading cause of disability worldwide (Moussavi et al., 2007), with 
lifetime prevalence in most countries ranging between 8 to 12% (Andrade et al., 2003). It is 
responsible for the greatest proportion of disease burden attributable to non-fatal health 
outcomes, accounting for almost 12% of total years lived with disability worldwide (Ustun and 
Chatterji, 2001). Major Depressive Disorder (MDD) in young people is estimated to be 
experienced by approximately 2% of children and 4% to 8% of adolescents (Birmaher et al., 
1996) and  carries its own burden of disadvantage often persisting or reemerging in adulthood 
(Weissman et al., 1999, Dunn and Goodyer, 2006). The Diagnostic and Statistical Manual of 
Mental Disorders 4th edition (DSM IV) considers major depression in adolescents and adults to 
be similar, although adolescents may show irritability rather than report depressed mood (APA, 
2000).  The 5th edition of the DSM (DSM 5) maintains these criteria (APA, 2011).  Similarities in 
the clinical presentation of MDD in children, adolescents and adults are supported by additional 
evidence (e.g. (Kovacs, 1996, Kaufman et al., 2001)), yet there is also support for differences in 
risk factors, clinical outcome, and biological correlates between adults and adolescents (Zisook 
et al., 2004, McDermott et al., 2010, Kaufman et al., 2001, Hill et al., 2004, Jaffee et al., 2002). 
Apparent differences in underlying aetiologies between adolescent- and adult- onset 
depression (Kaufman et al., 2001) may be attributable to developmental differences, or biologic 
changes that are sub-syndromal and too subtle for studies designed to detect the effect sizes 
reported in adult studies. Alternatively, it could be speculated that biologic changes observed in 
depressed adults but not in adolescents or children might be attributable to medication intake 
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since adults with depression often have a prolonged medication history as compared to 
adolescents and children with depression. 
Although there are differences in risk factors for depression in adolescent- and adult- 
onset depression, family history and stressful life events including childhood maltreatment are 
significant risk factors for both (Goodyer, 2008, Jaffee et al., 2002). A family history of 
depression does not automatically indicate a genetic contribution to the disorder, as it reflects 
both shared genetic and common (family) environmental effects. However, twin studies 
designed to tease out the heritability (proportion of variance that can be attributed to genetic 
factors), consistently indicate a substantial genetic component, particularly in clinical samples 
(e.g. (McGuffin et al., 1996)). Yet, identification of gene variants that robustly associated with 
depression have remained elusive, with environmental factors that interact with genetic 
predisposition being of potential relevance. A particularly important environmental mediator in 
depression is stressful life events, particularly childhood maltreatment (Nanni and Valentina, 
2012). Such experience may result in dysregulation of the adaptive stress response system 
(Danese et al., 2007). To investigate the interaction of genetic and environmental risk factors 
requires large data sets in which participants have provided DNA and have been consistently 
measured, preferably longitudinally, for environmental risk factors. Unfortunately, such data 
sets are rare. The on-going debate about the interaction between stressful life events and the 
serotonin transporter length polymorphism illustrates how differences in the measurement of 
environmental risk factors might, in part, be responsible for inconsistent findings between 
studies (Caspi et al., 2003, Risch et al., 2009, Karg et al., 2011, Uher et al., 2011, McGuffin et al., 
2011).   
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In adults, accumulating evidence suggests that MDD may be associated with immune 
system dysregulation (Irwin and Miller, 2007), at times occurring in the absence of specific 
immune challenges such as infections. Cytokines are signaling molecules that mediate key steps 
in cellular and humoral immunity, and a biological relationship with MDD is supported by a 
large number of mechanistic studies in vivo and in vitro (Dantzer et al., 2008).  Cytokine genes, 
such as variants of the IL-1β and TNF-α genes, have been implicated in impaired emotion 
processing in major depression and in hippocampus formation in recent fMRI studies (Baune et 
al., 2010, Baune et al., 2012b). Furthermore, a recent review suggested that genetic variants of 
cytokines are possibly involved in the pathophysiology of depression (Bufalino et al., 2012). Of 
particular relevance, cytokines have also been implicated in the stress response, important in 
depression (Szelenyi and Vizi, 2007). In both adults and adolescents, childhood maltreatment 
has been associated with an elevation in CRP levels, indicating a dysregulation of the immune 
system, further compounded by concurrent depressive symptoms (Danese et al., 2011, Danese 
et al., 2007). In addition, cytokines are implicated in neurodevelopment and with stress 
regulation since pro-inflammatory cytokines may exert direct effects on the hypothalamic-
pituitary-adrenal (HPA) axis (Janssen et al., 2010, Song, 2002). Prolonged periods of excess 
corticosteroids following chronic stress are particularly important during adolescence, as brain 
structures such as the hippocampus are susceptible to adverse stress-associated effects 
(McKittrick et al., 2000). Also, biological susceptibility to stress related brain damage may be 
heightened during adolescence when myelination processes within the central corticolimbic 
circuitry of the brain occur (Benes, 1989).  
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The primary purpose of this review is to assess literature on the role of cytokines in 
adolescent depression by identifying studies that measured both cytokines and symptoms of 
depression in adolescents. By doing this, we aim to clarify if cytokines have a differential role in 
depression in adolescents compared to adults.  The secondary purpose of this review is to 
examine how cytokines may be related to adolescent depression in the context of other 
neurobiological theories of depression.  
 
Method 
The literature search included published articles until February 2013 according to the 
PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines as 
they apply to systematic reviews (Liberati et al., 2009). The primary purpose was to identify all 
studies that provide empirical data on the measurement of cytokines and symptoms of 
depression in adolescents. In order to compare findings in adolescents to other age groups, the 
search was expanded to all age groups.  In addition, as some studies in older patients with MDD 
found a relationship between cytokines and cognition and cognitive dysfunction which may 
present as a symptom in depression, we also searched for studies that measured cytokines and 
cognitive performance in adolescents.  As a family history of depression is also considered a risk 
for MDD, ‘genes’ was included as a search term. To help identify publications considering a 
differential role for cytokines and immune markers in adolescent MDD, we conducted a further 
literature search applying the following combination of search terms – Cytokines, Immun*, and 
Depression and Stress. The final search strategy is illustrated in Figure 1.  
[Insert Figure 1 about here] 
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Results 
 Several detailed reviews have reported on the cytokine theory of depression (Haroon et 
al., 2011, Capuron and Miller, 2011, Dowlati et al., 2010, Janssen et al., 2010, Maes et al., 2009, 
Dantzer, 2009, Dantzer et al., 2008, Miller et al., 2009, Loftis et al., 2010, Sharpley and Agnew, 
2011), with a primary focus on adults, or older age groups. Our review comprises three main 
sections: (i) the cytokine theory of depression as reported in adults, (ii) evidence specifically 
relevant to adolescent-onset depression, and (iii) clinical implications.  
 
I. The Cytokine Theory of Depression  
Biological Properties of Cytokines 
Cytokines are small pleiotropic proteins (Khairova et al., 2009). The term cytokine 
includes a large and diverse family of signaling molecules that primarily have immune 
modulating activity, and are produced widely throughout the body by cells of diverse 
embryological origin (Ransahoff and Benveniste, 2006, Rothwell and Loddick, 2002). Cytokines 
can be viewed as either ‘pro-inflammatory’ or ‘anti-inflammatory’, depending on their primary 
effects on target cells (Khairova et al., 2009).  Pro-inflammatory cytokines include interleukin-
1α and β (IL-1α and IL-1β), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).  These 
molecules are believed to co-ordinate the local and systemic inflammatory response to 
microbial pathogens (Dantzer et al., 2008).  Others, such as interleukin 10 (IL-10), are 
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considered ‘anti-inflammatory’(Rothermundt et al., 2001), however this distinction of pro and 
anti-inflammatory cytokines has been regarded as an over-simplification in the context of 
depression (Janssen et al., 2010).  In the brain, as in systemic organs, the natural balance 
between pro- and anti-inflammatory cytokines regulates the intensity and duration of the 
response to immune stimuli (Dantzer et al., 2008).    
Heritability of cytokine levels (IL-1β, IL-1ra, IL-6, IL-10, and TNF-α) have been estimated 
to exceed 50% (De Craen et al., 2005). However, in this study cytokine levels were measured 
with an ex-vivo whole blood assay in response to lipopolysaccharide (LPS) stimulation, so 
heritability estimates may more accurately reflect “immune-response” and not necessarily 
naturally circulating levels of cytokines in the blood. Nonetheless, other studies based on 
circulating levels of cytokines implicate an important role for genetic factors (e.g.(Worns et al., 
2006, Sas et al., 2012, Raggi et al., 2010)). Dysfunction in genes controlling key proteins in 
cytokine production have been identified as vulnerability factors for cytokine-induced 
depression (Dantzer, 2009), and recent studies have reported that variation in IL-1 and TNF-α  
genes, and elevated levels of TNF-α, are associated with reduced responsiveness to 
antidepressant treatment (Jun et al., 2003, Rosa et al., 2004, Fertuzinhos et al., 2004). Overall, 
the molecular genetic basis of cytokine production in humans in the context of depression is 
currently not well understood.  
 
Cytokines and Depression 
Increasing evidence suggests that pro-inflammatory cytokines play a major role in the 
pathophysiology of depression. A role of cytokines in depression was first proposed by Smith in 
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the form of the ‘macrophage theory of depression’ stating that excessive secretion of 
macrophage monokines cause depression (Smith, 1991).  Although no consistent association 
between cytokines and MDD has been reported (Einvik et al., 2012, Steptoe, 2003), a recent 
meta-analysis that included 24 studies reported an association between elevated levels of two 
pro-inflammatory cytokines, IL-6 and TNF-α, and major depression (Dowlati et al., 2010).  
Additional research in humans is required to clarify whether cytokines are causally 
involved in clinical depression since the majority of studies have been cross-sectional (Sharpley 
and Agnew, 2011), with only a few prospective studies in humans allowing for causal 
inferences. For example, findings from a 12 year study of a large British occupational cohort in 
adults concluded that inflammation predicted cognitive symptoms of depression (Gimeno et al., 
2009). Moreover, in support of a role of inflammation in the etiology of depression, Baune et al. 
showed in older adults that the pro-inflammatory cytokine IL-8 predicted first onset of mild to 
moderate depressive symptoms over a 2 year period, indicating IL-8 could be a marker of first 
onset of depressive symptoms in the elderly (Baune et al., 2012c). Such studies are sparse in 
adolescents with clinical depression, and would require a longitudinal study design.   
A direct involvement of cytokines in clinical depression is supported by the view that 
interactions between biological factors and environmental conditions are significant in the 
etiology and pathophysiology of depression. For example, external factors such as psychosocial 
stressors and medical conditions such as organic inflammatory disorders or physiological 
conditions (i.e. the postpartum period), may trigger clinical depression via inflammatory 
processes (Maes et al., 2009). Clinical depression may also be induced by a therapeutic 
administration of interferon in hepatitis C (Udina et al., 2012). Experimentally, peripheral 
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administration of lipopolysaccharide (LPS), or of recombinant cytokines, such as IL-1β or TNF-α, 
induces nonspecific symptoms of sickness, including fever, activation of the HPA axis, reduction 
of food intake, and withdrawal from the physical and social environment, termed as sickness 
behaviour (Dantzer, 2009).  
Further mechanistic studies demonstrate that LPS not only causes a peripheral 
inflammatory response, but also induces a neuroinflammatory reaction with increased 
production of pro-inflammatory cytokines such as TNF-α in the brain (Qin et al., 2007, Kent et 
al., 1992). Pre-treatment with antidepressant drugs have also been found to abrogate LPS- or 
IL-1β- behaviour related to reduced consumption or rewards of sweetened solutions or sucrose 
in rats (Merali et al., 2003, Yirmiya et al., 1999). Although brain circuits involved in depression-
like behavior have been identified using LPS induction of cytokines in animal models (e.g., 
amygdala, hippocampus, hypothalamus), a functional dissociation between those brain 
structures that underlie cytokine-induced sickness behavior and cytokine-induced depressive-
like behavior has been reported, indicating the need for further research on the temporal 
relationship between cytokine elevation, structural and behavioural changes (Frenois et al., 
2007). Figure 2 shows the cellular and humoral immune factors implicated to have a role in 
depression.  Specifically, cellular neuroimmune mechanisms implicated in the pathophysiology 
of depression include dysfunction of T helper (Th 17) cells and CD4+CD25+ T regulatory (Treg) 
cells (Capuron and Miller, 2011, Eyre and Baune, 2011).  Findings on the possible involvement 
of natural killer (NK) cells in adult and adolescent MDD are discussed later.    
 
[Insert figure 2 about here] 
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Cytokines in the brain 
Cytokines can exert direct and indirect effects on brain function through their influence 
on neurotransmitters, neurogenesis, and the HPA axis influencing neuroplastic changes 
relevant to depression (Eyre and Baune, 2012). While cytokines do not readily pass through the 
blood-brain barrier (Haroon et al., 2011), five potential pathways for cytokine signals to reach 
the brain have been described:  1) passive transport of cytokines into the brain at 
circumventricular sites lacking a blood-brain barrier (Ericsson et al., 1994, Komaki et al., 1992, 
Breder et al., 1988); 2) activation of the cerebral vascular endothelium, thereby releasing 
cytokines and inducing the generation of secondary messengers such as prostaglandins and 
nitric oxide (Cao et al., 1997, Fabry et al., 1993, Kilbourn and Belloni, 1990); 3) carrier-mediated 
transport of cytokines into the brain across the blood-brain barrier (Banks et al., 1989); 4) 
activation by cytokines of peripheral afferent nerve terminals, which then relay cytokine signals 
to relevant brain regions (Watkins et al., 1994, Ericsson et al., 1994, Bluthe et al., 1994); and 5) 
recruitment of activated cells such as monocytes / macrophages from the periphery to the 
brain, where these cells can produce cytokines (D'Mello et al., 2009).  These mechanisms are 
not mutually exclusive, and depend in part on the location of the inflammatory stimulus and 
the disease state of the organism (Kronfol and Remick, 2000).  In addition, most cytokines can 
be synthesized and released within the CNS (Kronfol and Remick, 2000) such as by microglia 
that are a primary source of pro-inflammatory cytokine production in the brain (Miller et al., 
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2009). However, the brain circuitry that mediates the various behavioural responses to 
cytokines remains elusive (Dantzer et al., 2008).   
Clinical and experimental studies indicate that stress and depression are also associated 
with increased circulating concentrations of cytokines, such as TNF-α and IL-1 (Connor and 
Leonard, 1998).  Increased levels of these cytokines have the potential to impair synaptic 
plasticity (structurally and functionally), modulate long-term potentiation (LTP) and 
glutamatergic-dependent synaptic plasticity (Carlezon Jr. and Nestler, 2002, Du et al., 2004, Du 
et al., 2007, Du et al., 2008, Kendell et al., 2005, Malenka, 2003, Sun et al., 2005, Wolf et al., 
2004), and to induce fear learning, thus contributing to progression of a depressive disorder 
(Khairova et al., 2009). It has also been postulated that antidepressants indirectly modulate 
synaptic plasticity as a mechanism of antidepressant action, and that selective serotonin 
reuptake inhibitors (SSRIs) and tricyclic antidepressants may induce changes in TNF-α 
expression and function in the brain (Khairova et al., 2009). 
 
Cytokines influence on biological pathways of depression 
Cytokines affect biological pathways that have been associated with depression, and so 
the cytokine theory in depression can be viewed as complimentary rather than competitive to 
other hypotheses of depression, such as the monoamine theory of depression. Tryptophan is an 
essential amino acid required for protein synthesis and is a precursor for the monoamine 
serotonin and a lowered availability of plasma L-tryptophan has been associated with 
depression (Ruhe et al., 2007). Interestingly, decreased levels of L-tryptophan are also 
correlated with inflammation, indicating that systemic inflammation may contribute to clinical 
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depression via a decrease in the serotonin precursor L-tryptophan (Maes et al., 1993, Maes et 
al., 1996, Maes et al., 1990).  
As depicted in figure 3, pro-inflammatory cytokines induce IDO (indoleamine 2-3-
dioxygenase), an enzyme that mediates the catabolism of tryptophan into kynurenine (KYN) 
(Babcock and Carlin, 2000). KYN is further metabolized into 3-hydroxykynurenine (3-HK), 3-
hydroxyanthranilic acid (3-HAA), and quinolinic acid (QUIN), which may induce neuronal 
damage (Goldstein et al., 2000, Schwarcz et al., 1983).  Hence, it is suggestive that increased 
levels and activity of cytokines may lead to depressive symptoms by inducing a reduction in 
important neurotransmitters such as serotonin and by stimulating neuronal damage both 
implicated in clinical depression.  
[Insert Figure 3 about here] 
As cytokines, among other humoral and cellular immune factors, have the potential to 
influence systems heavily implicated in depression (Eyre and Baune, 2012), it is a clinically 
relevant question to determine if a genetic predisposition, or environmental factors that 
frequently associate with depression, or a combination of both, contribute to the 
pathophysiology of depression. It has been frequently reported that stress elevates levels of 
pro-inflammatory cytokines by activating their signaling pathways (Deinzer et al., 2004, Goebel 
et al., 2000, Madrigal et al., 2002, O'Connor et al., 2003). Moreover, cytokines influence the 
hypothalamic pituitary axis (HPA)(Capuron et al., 2003) and IL-1, IL-6, TNF-α, and IFN-α may 
increase corticotrophin-releasing hormone (CRH) release and disrupt the function of the 
glucocorticoid receptor (reviewed by (Cavanagh and Mathias, 2008)). Indeed, since a 
hyperactive HPA axis has been reported in a proportion of patients with MDD (Capuron et al., 
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2003), it is plausible that such hyperactivity could be a consequence of an elevation in 
cytokines, attributable to potentially both environmental and genetic moderators. Particularly 
genetic variants of cytokines have been suggested to be associated with clinical depression as 
recently reviewed by Bufalino et al. (Bufalino et al., 2012). However, the likely important 
interaction between these genetic variants and environmental factors such as stress and 
maltreatment has not been considered yet in original studies. 
Other genes of potential relevance are polymorphisms of the glucocorticoid receptor 
gene (NR3C1), involved in the regulation of the HPA axis. While some studies have reported 
that genetic variants of NR3C1 influence susceptibility to MDD and depressive symptoms 
(Szczepankiewicz et al., 2011), three further reports found no association, or associations that 
failed to withstand correction for multiple testing (van West et al., 2006, Mill et al., 2009). In 
addition, multiple genome-wide studies have presented no evidence for genome-wide 
significance (PGC, 2012). Failure to replicate may reflect insufficient power, due to insufficient 
sample size, heterogeneity of the phenotype of depression, or interaction with unidentified 
environmental factors. Indeed, evidence for gene-environment interaction has been reported 
with variation in the NR3C1 gene and childhood maltreatment (Bet et al., 2008), and altered 
methylation of the NR3C1 gene has been associated with stress exposure (Meaney and Szyf, 
2005, de Rooij et al., 2012).  These findings may lead to the speculation that depression could 
be a consequence of the effect of elevated cytokine levels in response to a stressor, occurring in 
the context of an NR3C1 system that was already dysregulated due to genetic or epigenetic 
effects earlier. 
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Recent work on the HPA axis and depression has also been conducted by Solomon et al., 
who showed a sex difference in the role of forebrain glucocorticoid receptors in regulating HPA 
axis activity and depression-like behavior in mice (Solomon et al., 2012).  Specifically, in mice 
with selective deletion of glucocorticoid receptors in forebrain cortico-limbic sites (forebrain 
glucocorticoid receptor knockout mouse – FBGRKO), female mice did not show basal HPA axis 
dysregulation or exaggerated stress responses. The authors noted that in females, 
glucocorticoid receptor regulation of HPA axis function and behavior may be from other brain 
areas than those targeted in the FBGRKO mouse (Solomon et al., 2012). 
Another biological pathway associated with depression might be a stress-induced 
decrease in neurogenesis influenced by cytokines. Pro-inflammatory cytokines, such as IL-1β, 
have been shown to inhibit cell proliferation and promote cell death in the hippocampus (Koo 
and Duman, 2008).  Furthermore, there is evidence that neurodegeneration and the defects in 
neurogenesis in depression are caused by inflammatory processes, related to the production of 
oxidative and nitrosative stress molecules and pro-inflammatory cytokines (Maes et al., 2009).   
Glutamate has also been implicated in MDD (Palucha and Pilc, 2007, Pittenger et al., 2007), and 
glutamate neurotoxicity represents a pathway leading to increased apoptosis enhanced by pro-
inflammatory cytokines via various pathways: (1) via activation of the kynurenine pathway in 
microglia and increased production of quinolonic acid and glutamate release; (2) via decreasing 
glial glutamate transporter activity leading to reduced glutamate removal from the extracellular 
space; and (3) by inducing long-term activation of microglia to release TNF-α and IL-1 in a 
positive feedback manner (reviewed in McNally et al 2008) (McNally et al., 2008, Khairova et 
al., 2009).  
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In summary, cytokines exert wide-ranging influences on neuronal structure, function, 
and directly on the stress-response system, as well as in response to stress.  Evidence for the 
role of cytokines in the brain in depression is building, and seems tantalizing, yet remains 
largely circumstantial.  Still needed is to clarify whether effects are causal in humans, to better 
specify the actual molecular mechanisms operating in human depression related to cytokines, 
and in particular to clarify the effects in adolescence.    
 
II. The Role of Cytokines in Depression in Adolescents  
Emerging literature has examined a possible role of cytokines in adolescent depression. 
A total of twenty-four articles examining the role of immune markers in depression in 
adolescents were identified for this review. Of these, eighteen studies report empirical data as 
summarized in Tables 1, 2, and 3. Twelve publications present case-control studies which have 
relatively small sample sizes; the largest study consisted of 134 cases and 149 controls.  Four 
studies used a prospective design (Miller and Chen, 2010, Caserta et al., 2011, Miller and Cole, 
2012, Copeland et al., 2012), assessing N=135, N=141, N=147, and N=1420 individuals 
respectively for depressive symptoms. The two remaining studies are a cross-sectional 
representative community sample (Chaiton et al., 2010), and an observational study of youths 
with diabetes (Hood et al., 2012). Key results from the studies are included in the relevant 
sections below.  Of the remaining 6 articles examining the role of immune markers in 
depression in adolescents, some did not measure cytokines (for example cytokine genes were 
genotyped but not circulating cytokine levels (Misener et al., 2008); Pandey et al. measured 
serotonin receptors postmortem and discussed the interaction between the HPA axis and 
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serotonergic system (Pandey et al., 2002)).  Two of these remaining 6 articles measured 
inflammatory markers or cytokines only when the cohort had reached adulthood (Danese et al., 
2008, Danese et al., 2007).  Of these 6 articles, the studies by Danese et al. 2007, Danese et al. 
2008, and Pandey et al. 2002 are discussed in more detail later in the review. 
 
Stress Response, Neurogenesis and Neurodevelopment 
Increased levels of pro-inflammatory cytokines in response to acute stress has been 
described as characteristic (Eyre and Baune, 2011), involving an activated HPA axis that may 
lead to a further rise in pro-inflammatory cytokines through complex positive feedback loops 
(Janssen et al., 2010). These mechanisms could be particularly important during adolescence, as 
brain structures such as the hippocampus appear susceptible to adverse effects of prolonged 
periods of excess corticosteroids with consequences such as atrophy of the apical dendrites of 
the pyramidal cells (McKittrick et al., 2000). Therefore, chronic unpredictable stress in the 
environment is regarded as an important factor in the development and onset of depression 
(Eyre and Baune, 2011).  
The variation in how an individual responds to stress, including their vulnerability to 
depression, may be influenced by an inflammatory response of the immune system. In a recent 
review, Fagundes et al. proposed a model of early adversity leading to greater stress sensitivity, 
and so placing an individual at greater risk for immune dysregulation (Fagundes et al., 2013).  
Elevated levels of inflammatory markers, specifically C-reactive protein (CRP), have been 
reported not only in depressed adults exposed to childhood maltreatment (Taylor et al., 2006, 
Danese et al., 2007, Danese et al., 2011), but also in adolescence (Danese et al., 2011).  CRP is 
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an acute phase protein that promotes resistance to infection and repair of damaged tissues 
(Danese et al., 2007). In these studies, CRP levels showed a linear increase depending on 
depression and/or maltreatment exposure (Danese et al., 2011, Danese et al., 2008). Individuals 
with a history of depression or current depression exhibited higher CRP levels relative to 
individuals with no depression or exposure to maltreatment; those with a history of 
maltreatment and no depression exhibited even higher levels of CRP, and finally those that had 
experienced both maltreatment and depression presented the most elevated profile of all the 
groups. The elevation in CRP levels was significant in the combined depressed and maltreated 
group, relative to those with no exposure to maltreatment or depression. The authors 
concluded that a history of childhood maltreatment has a significant role in explaining the co-
occurrence of depression and inflammation through the lifespan with “biological embedding” 
already seen at adolescence (Danese et al., 2011, Danese et al., 2008). The findings in 
adolescents (Danese et al 2011) are particularly important, as increased inflammatory markers 
in adulthood has been linked to increased risk of both mental and physical illness (Danese et al., 
2008, Miller et al., 2009).  
In adolescents, pro-inflammatory cytokines have also been implicated in the stress 
response with a higher number of stressful life events associated with higher TNF-α levels 
(Dixon et al., 2009).  In support of these findings is an 18-month longitudinal study of 
adolescent females who showed increased IL-6 responses to two different types of threatening 
stimuli on the background of exposure to a harsh family environment (Miller and Chen, 2010).  
An extension of this study that investigated circulating levels of IL-6 and CRP found that among 
those exposed to higher levels of childhood adversity, the transition to depression was also 
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accompanied by relative increases in both CRP and IL-6 (Miller and Cole, 2012).  Furthermore, 
the authors noted that higher CRP levels remained in these subjects 6 months later, even after 
the episode of depression had abated. Importantly, this coupling of depression and 
inflammation was not apparent in those without a history of childhood adversity (Miller and 
Cole, 2012).   
Cytokines also appear to be involved in neurodevelopmental processes (Wilson et al., 
2002); for example, IL-6 has demonstrated both neuroprotective (Peng et al., 2005, Godbout 
and Johnson, 2004) and neurodegenerative properties (Morales et al., 2010).  In support of a 
possible neuroprotective effect of IL-6 is a recently published neuroimaging study conducted in 
healthy individuals that showed increased hippocampus volumes associated with genetic 
variants of the IL-6 gene (Baune et al., 2012a). There is also some preliminary evidence 
suggesting that maternal psychopathology and HPA function influences fetal, infant, and 
adolescent HPA axis function resulting in a higher tonic setting of the HPA axis through 
epigenetic programming (Talge et al., 2007, Weaver et al., 2004). Psychiatric epigenetics is a 
relatively new field, however it does provide a biological mechanism by which stress might 
influence the immune response, and ultimately predispose to depression. Moreover, such 
mechanisms could lead to atypical early neurogenesis and vulnerable neural systems in the 
post-pubertal adolescent brain (Goodyer, 2008). Such a sensitization of the neurobiological 
systems implicated in stress adaptation and response (as is seen in childhood maltreatment) 
may increase the risk of developing depression (McCrory et al., 2010). Therefore, as individuals 
move through different stages of adolescence, the risk for depression as a consequence of 
stress exposure may change, and arguably so might the inflammatory stress-response profile. 
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To date little gene-environment work has focused on stress exposure and depression onset in 
adolescents specifically – the stress exposure has primarily focused on either adulthood or 
childhood (although this at times spans adolescent years) (e.g. (Fisher et al., 2012, Caspi et al., 
2003). 
 
Cytokines and onset of Depression during Adolescence 
Similarly to adult MDD, immune system dysregulation with a pro- and anti-inflammatory 
imbalance has been proposed in MDD in adolescents (Gabbay et al., 2009a). The first study to 
examine cytokines in adolescent MDD, reported increased pro-inflammatory cytokines IFN-γ 
and IFN-γ/IL-4 as well as a trend for increased IL-6 in adolescents with MDD compared to 
healthy controls (Gabbay et al., 2009a).   
In an attempt to examine the neurobiology of clinical subtypes of depression in 
adolescence, Gabbay et al. examined whether adolescent MDD with melancholic features (M-
MDD) has distinct biological features in the kynurenine pathway. As previously reported, pro-
inflammatory cytokines induce IDO, which metabolizes tryptophan (TRP) into kynurenine (KYN), 
eventually decreasing TRP availability in the brain (Gabbay et al., 2010). The authors reported 
decreased plasma TRP levels and an increased KYN/TRP ratio (estimating IDO activity) in 
adolescents with M-MDD compared to both non M-MDD and a control group. Interestingly, the 
severity of episodes as measured by Children’s Depression Rating Scale-Revised (CDRS-R) was 
associated with several KYN pathway measures (e.g., KYN and 3-hydroxyanthranilic acid (3-
HAA)/KYN) in the M-MDD group (Gabbay et al., 2010).   
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Investigating the relationship between early onset of depression and anxiety, IL-10 
levels have been associated with increased anxiety and depression scores, and IFNα2 levels 
with anxiety scores only (Quinones et al., 2012). The association between IFNα2 levels and 
anxiety scores remained significant after controlling for familial risk of MDD, gender, current 
stress, and childhood trauma (Quinones et al., 2012), suggesting an independent effect of 
cytokines in anxiety. 
Of clinical relevance is the potential that cytokine levels are modified during treatment 
with antidepressants (Janssen et al., 2010). In a clinical sample of adolescent females with MDD 
and/or anxiety disorder the effects of antidepressant treatment with SSRIs on cytokine levels 
was compared to healthy controls (Henje Blom et al., 2011). The overall sample showed 
significantly increased levels for IL-1β, IL-2 and IL-10 as compared to healthy controls , with 
SSRI-treatment associated with IL-6 levels in the clinical sample (Henje Blom et al., 2011). The 
non-SSRI subgroup showed significantly higher levels of IL-1β, IL-2, and IL-6 compared to 
healthy controls. The authors concluded that pro-inflammatory cytokines are likely to be part of 
the pathophysiology of emotional disorders in adolescent females, and that SSRIs may exert 
anti-inflammatory properties in this patient group (Henje Blom et al., 2011). 
 
Cytokine interactions with gonadal hormones 
The prevalence of major depression is known to increase during periods of changes in 
gonadal hormones (Bao et al., 2005). While the male-to-female ratio is 1:1 during childhood, 
the 1:2 sex ratio that characterizes adult MDD first emerges during adolescence (Birmaher et 
al., 1996). The timing of the change in male-to-female prevalence ratios for depression has 
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important implications for theories about the relationship between depression and puberty.  
Angold et al. reported early the role of secondary sex characteristics in the development of 
depression (Angold et al., 1998). Characteristics of gender development (sex characteristics) as 
expressed in Tanner stages ranging from I-prepubertal to V-adult level of development have 
been suspected to better associate with the development of depression rather than age.  It also 
appeared that this transition in gender prevalence ratios was a mid-pubertal event, occurring in 
Tanner stage III, generating theories about a role of gonadal hormones in the etiology of 
depression (Angold et al., 1998). . 
Research in pre-menopausal women indicates that gonadal hormones may modulate 
immune function (Schwarz et al., 1999, Verthelyi, 2001). The cytokine response of peripheral 
blood monocytes after LPS stimulation in premenopausal women appears to be modulated by 
the phase of the menstrual cycle (Schwarz et al., 1999). Specifically, a lower release of TNF-α 
(p<0.05) and IL-6 (not significant) during the luteal phase compared to the follicular phase was 
reported (Schwarz et al., 1999). Overall, however, findings on cytokine production across the 
normal menstrual cycle have been inconsistent (O'Brien et al., 2007a) requiring further 
investigations. In addition, it remains to be examined as to whether such findings derived in 
adult women would generalize and apply to younger age groups such as adolescents. 
Systematic research is required to determine if a relationship exists in adolescence between 
cytokines and hormones that are important for brain development. If such a relationship does 
exist, it will be important to determine if cytokines modulate gonadal hormones or vice versa. 
 
Differences in the Role of Cytokines in Depression between Adolescents and Adults 
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In this section, we aim to identify evidence for possible differences and similarities on 
the role of cytokines in adolescent and adult MDD. It is worthwhile to summarise the findings 
on the possible involvement of natural killer (NK) cells in adult and adolescent depression as an 
expression of immune activity in this psychiatric condition. While studies in adult MDD when 
compared to age consistent controls consistently demonstrate lower NK cell activity (Shain et 
al., 1991, Kronfol et al., 1989, Nerozzi et al., 1989, Irwin et al., 1990) and reduced number of 
major lymphocyte subclasses (Schleifer et al., 1984), studies of NK cell activity and lymphocyte 
subpopulations in adolescent MDD as compared to age consistent controls have yielded 
contradictory findings (Bartlett et al., 1995, Birmaher et al., 1994, Schleifer et al., 2002, Shain et 
al., 1991, Targum et al., 1990). Some of these inconsistencies in adolescent MDD might be 
related to methodologies such as accounting for adverse life events in some studies (Birmaher 
et al., 1994), or sampling of younger age groups (i.e. inclusion of both  children and 
adolescents) (Bartlett et al., 1995) or gender specific findings in girls (Caserta et al., 2011).  
 [Insert table 1] 
A meta-analysis of studies examining the association between depression in adults and 
elevated levels of the inflammatory marker CRP have also yielded inconsistent results (Kuo et 
al., 2005).  In adolescents, a large population-based study has found no apparent association 
between CRP and depressive symptoms (Chaiton et al., 2010). Although this first study indicates 
there may be a difference between adult and adolescent levels of CRP in depression, problems 
with this study include a lack of clinical diagnosis. In a meta-analysis of the associations of 
depression with CRP, IL-6, and IL-1, Howren et al. noted the importance of the method used to 
assess depression, with larger associations noted in clinical samples and when standard clinical 
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interviews were used to assess depression (Howren et al., 2009).  Copeland et al. used a 
structured interview to assess depression in a study examining longitudinal pathways between 
CRP and depression in adolescents and young adults (Copeland et al., 2012). The authors found 
that cumulative depressive episodes predicted later CRP levels after adjusting for important 
covariates (covariates of sex, age, body mass index (BMI), current nicotine/ alcohol/ illicit drug 
use, current medication use, recent health ailments, and current low socioeconomic status) 
(Copeland et al., 2012).   
Heterogeneity in results from both adult and adolescent studies may be due to no 
consideration of other variables that influence inflammation, such as stressful life events (Miller 
and Cole, 2012, Danese et al., 2011) . Addressing such a potential confounder, Brambilla et al 
examined the immune function of children with a first episode of MDD unlikely to have been 
preceded by stressful events. Contrary to that seen in depressed adults, those children without 
the experience of stressful life events with MDD had normal IL-1β levels (Brambilla et al., 2004). 
However, it is likely that several depression studies in adults have not accounted for stressful 
life events, limiting a direct comparison with the study by Brambilla.   
Many studies in adult MDD have reported increased TNF-α compared to controls 
suggesting a role in the pathophysiology of depression (Tuglu et al., 2003, Leo et al., 2006, 
Pavon et al., 2006, Kim et al., 2007, Dowlati et al., 2010).   However, when studying suicidality in 
adult MDD, studies on its relationship with cytokines have not always included assessment of 
TNF-α (Mendlovic et al., 1999, Kim et al., 2008). A study which did include measurements of 
TNF-α in suicidal adults found increased levels of TNF-α (and IL-6) in suicide attempters 
compared to non-suicidal depressed patients and healthy controls (Janelidze et al., 2011).  In 
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adolescents, contrasting findings were reported. Gabbay et al found that plasma levels of TNF-α 
were significantly decreased in suicidal adolescents with MDD compared to a nonsuicidal MDD 
group (Gabbay et al., 2009b).  However, the authors noted their findings should be considered 
preliminary in view of the small sample size (30 patients, 15 controls), and the substantial 
percentage (57%) of patients receiving psychotropic medications (Gabbay et al., 2009b). The 
authors also noted that due to the small sample size, in order to preserve statistical power, a 
multiple comparison correction was not applied (Gabbay et al., 2009b).  
If these findings in vivo hold true, postmortem studies suggesting the serotonergic 
system of the prefrontal cortex (PFC) is implicated in suicide in both adolescents and adults 
(Mann et al., 1989, Pandey et al., 2002), provide a possible pathway linking TNF-α levels to 
suicidality (Gabbay et al., 2009b).  A proposed mechanism to explain how cytokines may affect 
behavior is through activation of the enzyme IDO, which results in altered serotonin 
metabolism (Tonelli et al., 2008, Capuron and Miller, 2004). Specifically, increased 5-HT2A 
receptor binding has been observed in the PFC of teenage (Pandey et al., 2002) and adult 
suicide victims (Arango et al., 1997).  In addition, serotonin has been observed to be depleted in 
multiple brain regions, including the frontal cortex, in rodents acutely administered IFN-α by 
intracerebroventricular injection (Kamata et al., 2000).   
Importantly, cytokines in the brain of suicide victims, or subjects with depression, have 
not been systematically studied (Pandey et al., 2012), and the direction of their association 
remains to be fully understood.  For example, Pandey et al. observed that the mRNA levels of 
TNF-α, IL-1β, IL-6, and protein levels of TNF-α and IL-1β were significantly increased in 
Brodmann area 10 of the PFC of teenage suicide victims (compared to controls) (Pandey et al., 
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2012).  Interestingly, Tonelli et al. found no significant change in TNF-α in male or female adult 
suicide victims, however observed increased IL-4 in female suicide victims and increased IL-13 
in male suicide victims (Tonelli et al., 2008). It is possible that these studies are not directly 
comparable (Pandey et al 2012; Tonelli et al., 2008), as the pathophysiology of teenage suicide 
and the role of cytokines in teenage suicide may differ from that in adults (Pandey et al., 2012).   
                     [Insert Table 2 about here] 
 
In summary, studies that provide empirical data for a role of cytokines in adolescent 
MDD currently show similarities and differences between adolescents and adults, not allowing 
definite conclusions at this stage. Similarities include increased IL-6 levels, and decreased 
plasma TRP levels (Gabbay et al., 2009a, Gabbay et al., 2010).  Differences in IL-1β variation 
have been reported, with normal levels in “un-stressed” children with MDD (Brambilla et al., 
2004) and elevated levels in adults with MDD (Maes et al., 1991). Plasma TNF-α was noted to 
be significantly decreased in adolescents with MDD and suicidality (Gabbay et al., 2009b), yet 
mRNA levels of TNF-α were significantly increased in the PFC of teenage suicide victims (Pandey 
et al., 2012).  A meta-analysis in adults with MDD, regardless of suicidality, suggests a 
consistent association between circulating levels of TNF-α and adult MDD (Dowlati et al., 2010). 
Therefore, results for TNF-α are inconsistent between studies, however cytokines have been 
measured from different sites (for example, plasma in Gabbay et al. 2009b, versus postmortem 
brain tissue in Pandey et al. 2012).  In addition, it remains to be clarified, if suicidality alone 
could account for the differences in cytokines reported in MDD studies in adults and 
adolescents.  
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Small sample sizes in most of the studies on adolescents limit conclusions (e.g. 33 
individuals in the Brambilla et al. study, and 45 individuals in the studies by Gabbay et al. 2009a 
and Gabbay et al. 2009b). Furthermore, there are significant differences between many of the 
study protocols, such as cross-sectional studies of hospital inpatients (e.g. a proportion of 
patients in Gabbay et al. 2009a and Gabbay et al. 2009b were inpatients) versus longitudinal 
population-based observational studies (e.g. Copeland et al. 2012, Miller and Cole, 2012), 
prohibiting a formal meta-analysis. Further research using epidemiological approaches 
(Dantzer, 2012) in well-powered and well-designed cohorts is required to provide empirical 
data to consolidate and build on these results. 
[Insert table 3 about here] 
 
III. Clinical Implications  
Antidepressant drugs appear to have some action on pro-inflammatory cytokines 
(Bengtsson et al., 1992, Xia et al., 1996), with  attenuation of an imbalance between pro- and 
anti-inflammatory cytokines in patients with MDD treated with the antidepressants fluoxetine, 
sertraline, or paroxetine (Kim et al., 2007, Kubera et al., 2000, Sutcigil et al., 2007, Taler et al., 
2007, Tuglu et al., 2003).  Furthermore, patients who fail to respond to antidepressants have 
been found to demonstrate increased plasma concentrations of IL-6 and acute phase reactants 
when compared to treatment-responsive patients (Sluzewska et al., 1997, Maes et al., 1997, 
O'Brien et al., 2007b).   
Other agents and treatment programs that have anti-inflammatory actions or block 
actions of cytokines, such as physical exercise and omega-3 polyunsaturated fatty acids, may 
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have a role in the treatment of depression. It is possible that physical exercise may exert similar 
anti-inflammatory effects beneficial to improving depressive symptoms, which are believed to 
be more globally mediated through various pathways of the neuroimmune system (Eyre and 
Baune, 2011).  As recently extensively reviewed by these authors, consistent exercise / physical 
activity has been shown to reduce levels of IL-1β, TNF-α, IL-6, and CRP (Eyre and Baune, 2011), 
whereas studies examining the cytokine levels during or immediately after exercise have shown 
an upregulation of IL-6 and IL-8 (Fischer, 2006, Pedersen, 2009). The short-term effects of 
exercise with an acute transient upregulation of IL-6 appears to induce a rise in IL-10 
(Steensberg et al., 2003), and to negate neurotoxic changes of TNF-α (Funk et al., 2011).  
Further research has been recommended to enhance alternative treatment approaches to 
depression, such as physical exercise, that might improve depression via the immune system 
(Eyre and Baune, 2011). 
A meta-analysis of 10 double-blind, placebo-controlled studies in adult patients with 
mood disorders receiving omega-3 PUFAs, indicated an antidepressant effect of omega-3 PUFAs 
(Lin and Su, 2007). However, the authors noted that it is premature to draw firm conclusions 
based on the findings due to the heterogeneity of the different study methodologies (Lin and 
Su, 2007). Similar effects have also been reported for children in a small randomized controlled 
trial study showing that long chain omega-3 PUFAs supplementation in the treatment of 
children with a first episode of depression had a benefit in reducing depressive symptoms, 
however not in achieving remission (Nemets et al., 2006). Given the implication of omega-3 
PUFAs in depression, it is therefore interesting that omega-3 PUFAs have the capacity to 
decrease the production of pro-inflammatory cytokines, and exert strong anti-inflammatory 
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effects (Maes et al., 2009); studies in adolescents could add valuable knowledge to the 
literature.   
In studies of adults with depression, cytokine antagonists have also been found to have 
antidepressant-like effects (Mendlewicz et al., 2006, Krishnan et al., 2007, Tyring et al., 2006, 
Yirmiya, 2000, Raison et al., 2012, Dantzer et al., 1999).  TNF-α blockers such as etanercept and 
infliximab have been found to attenuate the depressive symptoms that accompany immune 
system activation in psoriasis (Krishnan et al., 2007, Tyring et al., 2006, Yirmiya, 2000, Dantzer 
et al., 1999).  However, conflicting results have been reported for TNF-α antagonists such as 
infliximab in that depressed patients with higher levels of CRP prior to treatment may benefit 
from such treatment as opposed to a general benefit in depression (Raison et al., 2012).  
Anti-inflammatory medications have also been found to have antidepressant-like 
effects.  For example, acetylsalicylic acid added to fluoxetine led to increased remission rates in 
depressed patients previously unresponsive to fluoxetine alone (Mendlewicz et al., 2006).   
Furthermore, in patients with MDD adding the cyclooxygenase-2 (COX-2) inhibitor celecoxib to 
treatment with reboxetine (Muller et al., 2006) or sertraline (Abbasi et al., 2012) induced an 
antidepressant response. Interestingly, Abbasi et al. also showed a significantly greater 
reduction in serum IL-6 concentrations in the group treated with celecoxib and sertraline 
(compared to the group treated with sertraline) (Abbasi et al., 2012)   .      
It has been noted that selectively targeting COX-2 in the treatment of depression may 
be problematic (Maes, 2012).  Consistent with determining the mechanism of action of COX-2 
inhibitors in depression, Maes reviewed possible detrimental effects of COX-2 inhibitors 
targeting pathways involved in depression.  He concluded that treatments with COX-2 inhibitors 
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may aggravate the pathophysiology of depression, through involvement in pathways which 
include lowering of antioxidant defenses and inducing neuroinflammation (Maes, 2012).  As 
anti-inflammatory treatments and the use of cytokine antagonists are less common in 
adolescents than in adults, further research is required to determine if interventions that act on 
immune responses are effective interventions for depression in adolescent populations.  
 
 
Conclusion 
A substantial body of literature has now focused on the association between cytokines 
and depression, primarily in adults with less extensive research in adolescents (Sharpley and 
Agnew, 2011).  However, this review shows that the role of cytokines in adolescent depression 
is characterized by many similarities with adult MDD, although important differences of 
cytokines in depression between these age groups may be emerging.  
The relatively small number of studies on the role of cytokines in adolescent MDD has to 
be taken into account alongside with several methodological issues, which limit their 
comparability among studies in adolescents but also with research in adults. In general, the 
sample sizes of these studies are small and few have employed a prospective design. This could 
particularly be an issue if altered cytokine levels are a consequence of illness, rather than a 
cause. If this is the case, altered cytokine levels in adolescence would be more subtle, and so 
larger sample numbers would be required to detect them statistically, compared to adult 
studies where changes might be more established and pronounced. 
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Depression in children and adolescents show some different immune and inflammatory 
changes to those seen in adult depression in the current literature, with contradictory findings 
of NK cell activity, and differences in pro-inflammatory cytokines such as IL-1β and TNF-α (Shain 
et al., 1991, Brambilla et al., 2004, Gabbay et al., 2009b, Pandey et al., 2012). Some of the 
reported differences between the role of cytokines in depression could be influenced by 
neurodevelopment, hormonal changes, stress, and trauma, with more direct effects in young 
individuals as they experience developmental changes compared to adults. An improved 
understanding of the role of cytokines in adolescent MDD also in relation to stress, 
maltreatment, hormonal changes and genetic background may inform aetiology and treatment 
options in adolescent depression.   
Further research is warranted to explore more broadly the role of cytokines in 
depression of adolescents considering adequately the neurobiological, hormonal and 
environmental changes young individuals are undergoing. Moreover, additional treatment 
options might be suitable in some forms of inflammation associated depression in adolescents.  
Initially, the field could be progressed with the inclusion of measurements of circulating 
cytokines, such as IL-1β, IL-6, and TNF-α, in intervention studies in adolescent MDD. Later, 
interventions that change levels of circulating plasma cytokines in adolescents with MDD may 
prove worthy of investigation. Importantly, future research requires well-designed, well-
powered clinical studies that consider environmental factors (in particular stressful life events), 
in addition to using genetic, developmentally, and physiologically sensitive designs with 
prospective community-based studies, as well as psychiatric samples (Goodyer, 2008). 
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 Figure 1: Study inclusion flowchart  
 
 
 
 
 
Legend:  
Inclusion criteria: Search was carried out applying the following combinations of terms – 1. 
Cytokines AND adolescents AND depression, 2. Cytokines AND adolescents AND cognition, 
3.Cytokines AND depression AND genes, 4. Cytokines AND cognition AND genes, 5.Cytokines 
AND depression AND cognition, 6.Cytokines AND immun* AND depression AND stress.   
Exclusion criteria: articles written in languages other than English 
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Figure 2 Immunological Factors involved with Depression 
 
 
Key: IL= interleukin; IFN= interferon; NK= natural killer cells; TNF= tumor necrosis factor; Th = T 
helper cell; T reg = regulatory T cells 
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Figure 3: Tryptophan pathways 
 
 
Key: 5-HT= 5-hydroxytryptamine; HAA=hydroxyanthranilic acid; HK= hydroxykynurenine;  
IDO= indoleamine 2-3-dioxygenase; ↑IDO= increased levels of IDO; IFN= interferon; IL= 
interleukin;  
NMDA= N-methyl-D-aspartate; QUIN= quinolinic acid; TNF= tumor necrosis factor;  
TRYCATS= tryptophan catabolites along the IDO pathway 
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Table 1: Studies of Immune Markers in Depression in Adolescents 
Study 
 
Objectives Design Immune 
markers  
Results 
Targum et 
al., 1990 
 
Determine if hospitalized adolescents with 
MDD or conduct disorder (CD) show reduced 
lymphocyte populations compared to 
controls, and whether there is an association 
between reduced lymphocyte nos / 
subpopulations and cortisol dysregulation in 
hospitalized adolescents 
 30 (11 patients 
with MDD, ages 
15.5+/-1.6 yrs; 11 
with conduct 
disorder (CD), 
ages 15.3+/-1.2 
yrs; 8 controls, 
ages 14.1+/-1.5 
yrs); cross-
sectional study 
 
 
 Total T cells, 
CD4+, CD8+, 
CD16, total B 
cells 
 
No significant differences 
on any lymphocyte 
measure between 
patients and controls 
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Shain et 
al., 1991 
 
 
To compare natural killer (NK) cell activity 
in depressed adolescent patients with NK 
cell activity in age- and sex-matched 
controls 
32 (16 patients, 
16 controls), 
ages 13-18 yrs; 
cross-sectional 
study 
NK cell 
activity 
 
No significant differences 
between patients and 
matched controls.  Age 
significantly correlated 
with NK cell activity. 
Birmaher 
et al., 1994 
 
 
Determine whether adolescents with MDD 
have disturbances in their cellular 
immunity, and to study whether the 
immunological changes detected are 
specific to depression or are general 
responses to stress 
54 (20 patients 
with MDD, 17 
non-depressed 
patients with 
conduct 
disorder (CD), 
17 healthy 
controls), ages 
11-18 yrs, 
Tanner stage III 
NK cell 
activity, 
lymphocyte 
subtypes 
 
Patients with CD 
significantly higher 
absolute number of B 
cells than healthy 
controls (p=0.02), and a 
significantly greater % of 
B cells than MDD group 
(p=0.05) and controls 
(p=0.02).   
Patients with CD (who 
 52 
or more; cross-
sectional study 
had significantly more 
adverse life events) 
showed a trend for lower 
NK cell activity than 
those in the MDD group 
(p=0.08) and the control 
group (p=0.08). 
Bartlett et 
al., 1995 
 
To examine for differences in immunity 
between children with MDD and healthy 
controls 
36 (18 patients, 
18 controls),  
ages 8-12 yrs; 
cross-sectional 
study 
 
Total white 
blood cells 
(wbc), 
lymphocytes, 
T cells, B cells, 
monocytes, 
NK cells, 
CD4+, CD8+ 
Lowered NK cell activity 
in depressed subjects 
compared to healthy 
controls (p<0.001). 
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cells 
Schleifer et 
al., 2002 
 
To determine if immune changes in MDD 
are age-related 
72 (36 patients, 
36 healthy 
controls), ages 
14-20 yrs; 
cross-sectional 
study 
 
 
Total wbc, 
lymphocytes, 
granulocytes, 
monocytes, T 
cells, B cells, 
CD4+, CD8+, 
CD29+,  
CD45RA+, NK 
cells, HLA-
DR+ cells 
Increased levels of 
lymphocytes, T cells, B 
cells, CD4+, and CD29+ 
lymphocytes in 
depressed group 
compared to controls 
(p<.05).    Increased NK 
cell activity in MDD 
adolescents (p< .001)  
 
Caserta et 
al. 2011 
To test the hypothesis that self-reported 
efficacy and depression would predict 
immunity and rate of illnesses.    
141 children; 
assessed on 3 
occasions, 6 
months apart; 
IL-6, NK cell 
functional 
assay 
Negative association 
between self-efficacy and 
IL-6 (p=0.03); depression 
was associated with 
 54 
self-efficacy  
measured by 
self-report; 
parents 
recorded 
illness (mental 
health 
problems were 
not coded as 
illness);  
longitudinal 
study; age 7-13 
years (median 
age 9.3 years) 
increased NK cell 
function (p=0.02) and 
higher rates of illness 
(p<0.01) in girls older 
than 9.3 years of age; 
Key: CD= Conduct Disorder; CD cells= Cluster of Differentiation; MDD= Major Depressive Disorder; NK cells= natural killer cells;  
wbc= white blood cells
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Table 2: Clinical Studies of Cytokines / Inflammatory Markers in Depression in Adolescents 
Study 
 
Objectives Design Inflammatory 
Markers 
Results 
Brambilla 
et al., 2004 
To determine whether cytokine secretion 
is impaired at an early phase of 
development of depression, possibly 
involvement in the course of the disease 
33 (22 patients, 
11 
psychologically 
healthy 
controls),  ages 
6-14 yrs; cross-
sectional study 
Plasma IL-1β, 
TNF-α 
 
IL-1β levels significantly 
higher (p<0.0003, z= -
2.95) and TNF-α lower 
(p<0.01, z= -2.53) in 
dysthymic patients than 
in controls;  IL-1β and 
TNF-α not significantly 
different between MDD 
and controls.  
Gabbay et 
al., 2009a 
To examine immune system dysregulation 
in adolescents with MDD 
45 (30 patients, 
15 healthy 
controls), ages 
Plasma IFN-γ, 
TNF-α, IL-6,  
IL-1β, IL-4 
Significantly increased 
plasma level of IFN-γ 
(p<0.003, Bonferroni 
 56 
12-19 yrs; 
cross-sectional 
study 
corrected p<0.02) and 
IFN-γ/IL-4 ratio 
(p=0.007, Bonferroni 
corrected p<0.05) in 
adolescents with MDD; 
Trend for increased IL-6 
in adolescents with 
MDD compared to 
controls (p=0.09) 
Gabbay et 
al., 2009b 
To examine the role of cytokines in suicidal 
symptomatology in adolescent MDD 
Patient group 
as above (30 
patients – 12 
suicidal, 18 
non-suicidal; 15 
controls); 
Plasma IFN-γ, 
TNF-α, IL-6, IL-
1β, IL-4 
Suicidal adolescents had 
significantly decreased 
plasma levels of TNF-α 
compared to non-
suicidal adolescents 
with MDD (p=0.03);  
 57 
cross-sectional 
study 
Increased IFN-γ in both 
suicidal (p<0.02) and 
non-suicidal (p=0.005) 
adolescents with MDD 
compared to controls; 
Gabbay et 
al., 2010 
To examine whether MDD in adolescents 
has distinct biological features in the 
kynurenine pathway in MDD case with (M-
MDD) and without (Non M-MDD) 
melancholic features; 
20 adolescents 
with M-MDD, 
30 adolescents 
with non M-
MDD, 22 
healthy 
controls.  Ages 
12-19yrs. 
Cross-sectional 
study 
Plasma TRP, 
KYN, 3-HAA 
KYN/TRP ratios 
significantly elevated 
and TRP concentrations 
significantly reduced M-
MDD group compared 
to non M-MDD 
adolescents (p=0.001; 
p=0.006 respectively), 
and controls (p=0.008; 
p=0.02 respectively); 
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Significant positive 
correlation between 3-
HAA/KYN and MDD 
severity in the M-MDD 
group (p=0.03); 
Henje 
Blom et al. 
2011 
To study effects of antidepressants on 
systemic cytokines in post pubertal 
adolescent females with anxiety disorders 
and/or MDD compared to healthy controls 
42 adolescent 
females with 
MDD, 60 
healthy 
controls; age 
14 – 18 years; 
cross-sectional 
study 
Plasma IL-1β, 
IL-2, IL-6, IL-10, 
IFN-γ, TNF-α 
Unmedicated subgroup 
of clinical sample 
showed significantly 
higher IL-2, IL-1β and IL-
6 compared to controls 
(adjusted Z= -3.3, 
p<0.001; adjusted Z= -
2.2, p<0.05; adjusted Z= 
-2.3, p<0.05 
respectively);  in the 
 59 
medicated subgroup, 
only IL-2 was 
significantly higher as 
compared to 
controls(adjusted Z= 
2.3, p<0.05).  
Unmedicated subgroup 
of clinical sample 
showed significantly 
higher IL-6 and IL-6/IL-
10 compared to 
medicated subgroup 
(adjusted Z= 2.8, 
p<0.001, adjusted Z= 
2.5, p<0.05 
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respectively);  
Pandey et 
al. 2012 
To examine the role of pro-inflammatory 
cytokines in suicide 
24 suicide 
victims, 24 
controls.  
Cause of death 
for the controls 
varied (e.g 
heart disease, 
motor vehicle 
accident); 
unclear if 
controls ever 
attempted 
suicide;  Ages 
12-20 years; 
Protein and 
mRNA levels of 
TNF-α, IL-1β 
and IL-6 in 
prefrontal 
cortex 
Significantly increased  
mRNA levels of TNF-α, 
IL-1β and IL-6 in 
Brodmann area 10 of 
the PFC in suicide 
victims(p<0.01).  
Significantly increased 
protein levels of TNF-α 
and IL-1β in Brodman 
area 10 of the PFC in 
suicide victims (p<0.01) 
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cross-sectional 
study 
Quinones 
et al. 2012 
To further understand the role of specific 
immune mediators early in the 
development of depression and anxiety 
A group at high 
familial risk for 
MDD (n=134), 
and an age and 
sex matched 
low-risk group 
(n=149); no 
previous mood 
disorder or 
substance 
abuse 
diagnosis.  Ages 
12-15 years; 
Plasma 
cytokine levels 
IL-10 was significantly 
associated with anxiety 
and depression scores; 
IFNα2 levels were 
correlated with anxiety 
scores independent of 
familial risk for mood 
disorders and 
environmental stressors 
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cross-sectional 
study 
Key: CRP= C-reactive protein; HAA= hydroxyanthranilic acid; IFN= interferon; IL= interleukin; KYN= kynurenine;  
LPS= lipopolysaccharide; MDD= Major Depressive Disorder; M-MDD= Major Depressive Disorder with melancholic features; NK cell = 
natural killer cell; TNF= tumor necrosis factor; TRP= tryptophan 
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Table 3: Population based Epidemiological Studies of Cytokines / Inflammatory Markers in Adolescents 
Study Objectives Design Inflammatory 
Markers 
Results 
Miller and 
Chen, 2010 
To evaluate if a harsh environment 
engenders a pro-inflammatory 
phenotype in children that is marked 
by exaggerated cytokine responses to 
bacterial stimuli and the anti-
inflammatory properties of cortisol 
135 adolescent 
females, 
assessed at 4 
occasions over 
an 18 month 
period 
(prospective 
study).  No 
history of 
chronic medical 
or psychiatric 
disorders; Ages 
Circulating 
serum IL-6, 
production of 
IL-6 following 
LPS 
stimulation, 
and resistance 
to 
glucocorticoids  
Those raised in a harsh 
environment showed 
increased IL-6 response 
to 2 different types of 
threatening stimuli - in 
vitro LPS (p=0.01) and a 
stressful life event 
(p=0.001).  Over this 
time, subjects also 
showed progressive 
desensitization of the 
glucocorticoid receptor 
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15-19 yrs at 
time of study 
entry 
(p=0.04) 
 Chaiton et 
al., 2010 
To study the association between high-
sensitivity C-reactive protein concen-
trations and depressive symptoms in 
youth 
1,535 (721 
aged 13 yrs, 
814 aged 16 
yrs); cross-
sectional study 
CRP No apparent association 
between depressive 
symptoms and serum 
CRP (p=0.81) 
Copeland 
et al., 2012 
To test 1. Effect of CRP levels on later 
depression status; 2. Effect of 
depression status on later CRP levels; 3. 
Effect of cumulative episodes of 
depression on later CRP levels 
1,420 children, 
ages 9, 11, and 
13 years at 
intake;  
longitudinal 
study, with 
annual 
CRP (measured 
in dried blood 
spot samples) 
CRP levels were not 
associated with later 
depression status.  CRP 
levels increased with 
number of prior 
depressive episodes.  
Only cumulative 
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assessments to 
age 16 years, 
and again at 
ages 19 and 21 
years;  
depression 
assessed by a 
structured 
interview  
depressive episodes 
predicted later CRP 
levels after controlling 
for covariates (p= 0.02) 
Miller and 
Cole, 2012 
1. To aim to clarify the direction of the 
association between depression and 
inflammation 
2. To determine whether other kinds of 
childhood adversity (besides childhood 
maltreatment) also promote clustering 
147 adolescent 
females, 
assessed every 
6 months over 
2.5 years.  Ages 
15-19 years at 
Serum CRP,  
IL-6 
High levels of IL-6 
predicted risk of 
depression 6 months 
later in those with a 
history of childhood 
adversity (serum IL-6 
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of depression and inflammation time of study 
entry; 
longitudinal 
study 
odds ratio 1.50, 95% CI 
1.10-2.06, p=0.01).  
Higher CRP levels 
remained 6 months 
after depressive 
episode had abated in 
those subjects exposed 
to higher levels of 
childhood adversity. 
(Hood et 
al., 2012) 
1. To provide preliminary evidence 
that the increased risk for 
depression in youth with diabetes 
is associated with metabolic and 
inflammatory markers 
2. To inform future examinations of 
2,359 youths 
with diabetes 
from the 
SEARCH study – 
an 
observational 
CRP, IL-6 CRP was significantly 
(p<0.006) associated 
with depression in 
youth with diabetes in 
bivariate analysis.  In 
regression models 
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the directionality of these 
associations 
study of US 
children 
diagnosed with 
diabetes at <20 
years of age.  
Mean age of 
study 
participants 
15.2 +/- 3.1 yrs 
stratified by diabetes 
type and accounting for 
demographic and 
clinical characteristics, 
only higher levels of 
apoB remained 
associated with higher 
levels of depression in 
youth with type 1 
diabetes. 
Key: CRP= C-reactive protein; IL= interleukin; LPS= lipopolysaccharide 
